SEC Form 15-12G filed by Myovant Sciences Ltd.
$MYOV
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-37929
MYOVANT
SCIENCES LTD.
(Exact name of registrant as specified in its charter)
7th Floor
50 Broadway
London
SW1H 0DB
United Kingdom
+44 207 400 3351
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Shares, par value $0.000017727 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
☒
|
|
|
Rule 12g-4(a)(2)
|
☐
|
|
|
Rule 12h-3(b)(1)(i)
|
☒
|
|
|
Rule 12h-3(b)(1)(ii)
|
☐
|
|
|
Rule 15d-6
|
☐
|
|
|
Rule 15d-22(b)
|
☐
|
Approximate number of holders of record as of the certification or notice date: 1
Pursuant to the requirements of the Securities Exchange Act of 1934, Myovant Sciences Ltd. has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.
|
Date: March 20, 2023
|
MYOVANT SCIENCES LTD.
|
|
|
By:
|
/s/ Matthew Lang
|
|
|
Name:
|
Matthew Lang
|
|
|
Title:
|
General Counsel
|
|